These authors performed a series of very elegant in vitro and in vivo experiments, showing that TGF-β produced by ovarian cancer cells can activate a TGF-β receptor/RAC1/SMAD-dependent signaling pathway in the mesothelial cells, what induces EMT and results in overexpression of fibronectin. Here, TGFB1 is linked to ovarian cancer.